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From Different Stem Cell Levels 
By Johannes W.G. Janssen, Bernd R. Anger, Hans G. Drexler, Claw R. Bartram, and Hermann Heimpel 
We  report  the  rare  occurrence  of  essential  thrombo- 
cythemia (ET) in two sisters. In one  patient, the clinical 
phenotype of the disease evolved from ET to polycythemia 
vera (PV) after 4 years of follow-up. Clonal hematopoiesis 
was established in both cases by X-chromosomal inactiva- 
tion analysis using a DNA polymorphism of the phospho- 
glycerate-kinase (PGK) gene. Cell separation studies sug- 
SSENTIAL THROMBOCYTHEMIA (ET) is a rare  E  chronic myeloproliferative  disorder characterized  by 
sustained elevation of the thrombocyte count, hyperplasia of 
the bone marrow with excessive proliferation of megakaryo- 
cytes, and a  high incidence of  thromboembolic complica- 
tions.'.'  Since an elevated platelet count is a common feature 
of  various infectious,  inflammatory or neoplastic  disorders, 
and is also frequently associated with other chronic myelopro- 
liferative syndromes such as polycythemia vera or idiopathic 
myelofibrosis, ET is diagnosed by exclusion, generally follow- 
ing the criteria of the Polycythemia Vera Study  Group.* 
The clonal  nature of  the disease  has  previously  been 
established by cytogenetic analyses demonstrating nonran- 
dom yet variable chromosomal abnormalities:  and by stud- 
ies  using  glucose-6-phosphate  dehydrogenase  (G-6-PDH) 
 isoenzyme^.'^'-^ Moreover, G-6-PDH analyses indicated that 
granulocytes, monocytes, thrombocytes, erythrocytes, and B 
lymphocytes share a common ancestral origin in the few ET 
patients investigated thus far. The latter approach, however, 
is limited  by the rarity of G-6-PDH heterozygosity outside 
certain ethnic groups.  This major detraction of  G-6-PDH 
analysis is overcome by the use of X-linked DNA polymor- 
phisms,  as recently  described by  Vogelstein et a1.103"  The 
DNA technique allows clonality to be studied in about 50% 
of females and is comprised of two steps: (1) the two copies of 
an X-linked  gene are distinguished through  a  restriction 
fragment length polymorphism (RFLP), and (2) active and 
inactive alleles are then differentiated by subsequent analysis 
of their methylation pattern. The method  has been used to 
demonstrate the  clonal nature of acute myeloid  leukemia^,'^.'^ 
myelodysplastic syndromes,14 and chronic myeloproliferative 
The present  report describes  the application of  this ap- 
proach to clonal analyses in two sisters with ET. Our data 
confirm the present  view of  ET as a clonal  hematopoietic 
disease and suggest, moreover, that this chronic myeloprolif- 
erative disorder  might  originate  from  different  stem cell 
levels. 
PATIENTS AND METHODS 
Case Histories 
Elevated thrombocyte and leukocyte counts were first 
documented when the patient underwent hysterectomy at the age of 
56  years.  Thrombocytosis was  sustained with  counts varying  be- 
tween 800 and  1,200 x  109/L at follow-up. The patient was  still 
asymptomatic 2 years later, and the spleen was not palpable. The 
white blood cell count was  17.7 x  109/L; erythrocyte count, 4.9  x 
10l2/L;  hematocrit level, 44%. thrombocyte count, 1,200 x  109/L; 
and the alkaline neutrophil phosphatase score was  129 (normal, 10 
Patient  1. 
gested a common ancestor for granulocytes, monocytes, 
and T lymphocytes in one patient; however, in her sister, 
monoclonality  could only be demonstrated convincingly for 
the granulocyte fraction. Our  data indicate that  ET  may 
originate from heterogenous stem cell levels. 
0  1990 by The American Society of  Hematology. 
to 100).  A bone marrow core biopsy showed an enhanced cellularity 
due to panhyperplasia of  myelopoiesis, erythropoiesis, and atypical 
megakaryocytes. Moderate diffuse myelofibrosis was seen. Cytoge- 
netic analysis from peripheral blood  showed  a normal  karyotype. 
Southern blot analysis showed a germline configuration of  the BCR 
gene. 
Two years later, at the time of the present examination,  the patient 
presented with a phenotypic change of  her chronic myeloprolifera- 
tive disorder, which  now  resembled polycythemia vera: erythrocyte 
count and hematocrit level rose to 7.2 x lO'*/L  and 58%, respectively; 
the thrombocyte count was  850 x  109/L; and the white blood cell 
count was  15.3 x  109/L with 72% neutrophils, 6% eosinophils, 1% 
monocytes, 19% lymphocytes, and 2% atypical lymphocytes. Mor- 
phology of  the bone marrow has not changed. The spleen is palpable 
3 cm below  the coastal margin. Currently, the patient is alive and 
treated with phlebotomies. 
Diagnosis of  ET in her  1-year-older  sister prompted 
patient 2 to ask for physical and hematologic examination. Indeed, 
ET was also diagnosed in her case, 4 months after establishment  of  a 
myeloproliferative  disorder  in  her  sister. At  that  time, she  was 
asymptomatic and showed  no organomegaly. The white blood cell 
count was  12.8  x  109/L with 64% neutrophils, 7% eosinophils, 1% 
basophils, 2% monocytes, and 26% lymphocytes; erythrocyte count 
was 4.4  x  10l2/L;  hematocrit level,  38%;  and thrombocyte count, 
1,400 x 109/L.  The score of the alkaline neutrophil phosphatase  was 
normal. A bone marrow core biopsy showed an enhanced cellularity 
with  hyperplasia  of  atypical  megakaryocytes.  Moderate diffuse 
myelofibrosis was  seen. Since there was a dry tap on bone marrow 
aspiration, cytogenetic  analysis was  not  possible.  Southern blot 
analysis established  a  germline configuration  of  the BCR gene. 
Currently the patient is well and followed without treatment. 
Essential thrombocythemia was diagnosed in both patients accord- 
ing to the criteria of the Polycythemia Vera Study Group.' Require- 
ments were  as follows: a sustained thrombocytosis above 600  x 
109/L, enhanced  cellularity of  the  marrow  with  hyperplasia  of 
immature megakaryocytes, normal or elevated score of  the alkaline 
Patient 2. 
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neutrophil  phosphatase  and absence of  the Philadelphia  chromo- 
some, exclusion of reactive thrombocytosis due to infectious, inflam- 
matory or neoplastic disease, no blood loss or iron deficiency, no 
erythrocytosis, and no high-grade myelofibrosis. 
The family history of the two sisters, having no additional siblings, 
is inconspicuous. Both live separately with their own families. 
Cell Separation Analyses 
Heparinized  peripheral  blood  and a skin biopsy  were obtained 
from the patients with informed consent. Lymphocytes, monocytes, 
and granulocytes were separated from 200 mL peripheral blood by 
Ficoll-Hypaque  (Lymphoprep;  Nyegaard, Oslo, Norway) density 
gradient centrifugation. Granulocytes were purified from erythro- 
cytes by dextran sedimentation. T lymphocytes were further isolated 
by  neuraminidase-treated sheep erythrocyte rosetting, followed by 
Ficoll density gradient centrifugation. Monocytes were enriched by 
adherence to plastic dishes (90 minutes at 37OC). Purity of the cell 
populations  was  examined  by  morphologic  inspection  of  May- 
Gruenwald-Giemsa-stained  cytospin slide preparations and indirect 
immunofluorescence staining using the microtiter plate method with 
cell lineage-specific monoclonal antibodies (MoAbs). The following 
MoAbs were used: MY7 (CDl3)  as a marker of myeloid cells; Leu-9 
(CD7) and OKT3 (CD3) for T lymphcoytes; B4  (CD19) and BI 
(CD20)  for  B  lymphocytes;  and  MY4  (CD14)  for  monocytes 
(MoAbs  MY4,  MY7,  B1,  and  B4  from  Coulter  Immunology, 
Hialeah, FL; OKT3 from Ortho Diagnostics, Raritan, NJ; Leu-9 
from Becton-Dickinson, Mountain View, CA). Positivity was ana- 
lyzed by  flow  cytometry using an EPICS C cell sorter (Coulter 
Electronics, Hialeah, FL). 
A fibroblast cell line was established from a skin biopsy obtained 
from the right leg of patient 2. 
Southern Blot Analysis 
High molecular weight DNA was prepared from leukocytes and 
skin fibroblasts by  standard techniques."  For  clonal analysis, we 
adopted the protocols of Vogelstein et al,"."  as described previously 
by us.13  For investigation with the hypoxanthin phosphoribosyltrans- 
ferase (HPRT) probe,  IO pg of  DNA was screened for a BumHI 
RFLP showing 24 kb and  12 kb fragments; for analysis with the 
PGK  probe, respective DNAs were  screened  for a  Bgl  I  RFLP 
characterized by  9.4 kb and  5.7  kb  fragments. DNAs  of  both 
patients were  only  heterozygous  for  the  PGK  RFLP that  was 
subsequently used for clonal analysis. DNA (20 pg) was codigested 
with BsrXI and Pst I, producing polymorphic fragments of  1.05 kb 
and 0.9 kb, and either not digested further or cleaved with Hpa 11, 
which, in  the case of  the PGK gene, identifies the unmethylated 
active allele. 'Restriction enzymes were obtained from Pharmacia 
LKB (Uppsala, Sweden), with the exception of  BstXI (New En- 
gland Biolabs, Beverley, MA). Restriction enzymes were used at a 
concentration  of  5  units/pg  of  DNA.  Electrophoresis  on  1.5% 
(PGK) or 0.6% (HPRT) agarose gels, Southern transfer to nylon 
membranes (Nytran; Schleicher & Schuell, Dassel, FRG), hybrid- 
ization, and washing of  filters was performed as described."  Filters 
were  exposed  to  Kodak  Xomat-S films  for  12 hours  to  7 days 
at -  7OoC using  intensifying screens. The following  probes were 
kindly provided by Drs J. Singer-Sam (Duarte, CA) and J. Respess 
(La Jolla, CA):  a 0.85 kb Msp I/Pst I insert from pPB 1.7 containing 
sequences from  the 5'  end of  the HPRT gene''  and pSPT/PGK 
containing a 0.8 kb EcoRI/BumHI fragment from the 5'  region of 
the PGK gene.Ig 
RESULTS 
After cell separation, the degree of  contaminating cells 
was 7% and 4% for the granulocyte fraction as  well as 3% and 
2%  for T lymphocytes of patients 1 and 2, respectively (Table 
1). The content of residual cells, mainly T lymphocytes, was 
rather high in the monocyte samples of  both cases; ie, 33% 
and 29%, respectively. 
Both  patients  were  suitable  for  clonal  analyses  due to 
heterozygosity  at the PGK  locus.  After Hpa  I1 digestion, 
peripheral, blood leukocytes showed the characteristic pat- 
tern of monoclonal hematopoiesis, as indicated by the loss of 
one allele represented by the 0.9 kb fragment in patient 1 and 
the 1.05 kb fragment in patient 2 (Fig 1A and B, lane 1). A 
monoclonal  pattern  is  defined  as  decrease  in  autoradio- 
graphic intensity by over 80%  for one allele and less than 40% 
for the other allele after Hpa I1  digestion." 
Marked differences between both cases became obvious in 
investigating  the separated cell fractions. In patient  1,  only 
the granulocytes showed a clear-cut monoclonal pattern (Fig 
1A). In contrast,  all  hematopoietic  cell  lines  analyzed in 
patient  2  (granulocytes, monocytes,  and  T  lymphocytes) 
exhibited a clonal composition (Fig 1B). The possibility that 
imbalanced mosaicism simulated the monoclonal pattern of 
the  latter  case  could  be  ruled  out  unequivocally,  since 
analysis of the patient's  fibroblasts established a 1:l ratio of 
active maternal to active paternal X-chromosomes (Fig lB, 
lane 5). 
The data concerning  the separated  monocyte  fractions 
must  be  interpreted  with  caution  due to the presence  of 
approximately 30% contaminating cells, mostly T lympho- 
cytes. In  patient 2, the clear-cut monoclonal pattern (Fig lB, 
lane 2) cannot readily be explained by the presence of clonal 
contaminants only, but  rather  reflects  involvement  of  the 
monocyte lineage in this case. The situation is less clear in 
Table 1.  Characterization of Separated Cell Fractions by Immunologic and Morphologic Examination 
~ 
Specificity  of MoAbs 
Patient 1  Patient 2 
Myeloid  Monocytic  T Cells  B Cells  Myeloid  Monocytic  T Cells  B Cells 
Cell Fraction  (CD13)  (CD14)  (CD7 + CD3)  (CD19 + CD20)  (CD13)  (CD14)  (CD7 + CD3)  (CD19 + CD20) 
Granulocytes  96  <1  4  il  88  <l  5  <l 
T cells  1  1  97  1  tl  <1  98  1 
Monocytes  ND  71  29  il  ND  77  20  3 
93  <1'  7'  96'  <1'  4' 
<l'  67'  33'  <1'  71'  29" 
Values express percentage of positive cells. 
Abbreviation: ND, not done. 
'  Morphologic evaluation of May-GrSnwald-Giemsa-stained  cytospins. 
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Fig 1.  (AI Chl  composition of  porlphml blood Iwkoytes 
(11.  as well as separated monocytes (21.  granutaytes (31;  and T 
lymphaqtcn (4) of patient 1. A PGK RFLP de6ned by 1  .OS kb and 
0.9 kb fragments in 8srXIIP.t I  digests distinguishes the maternal 
from the paternal allele, and methylation  dtferences, as shown by 
further Hps It  digestion, distinguish between active and inactive 
X-chromosomes.  DNA  (20 pg) was  digested  with BsrXIIPsr 1. 
Subsequently, the DNA was divided into equal aliquots; one was 
not digested further (b lanes), and the other was digested with Hpa 
II la lanes). A monoclonel pattern indicated by loss of ow  allele 
was observed in peripheral blood leukocytes (1  1 and granulocytes 
(3). while a polyclonal pattern emerged for monocytes (2) and T 
lymphocytes (4). (6)  Clonal composition of peripheral blood cell 
subpopulations  and  skin  fibroblasts  of  patient  2,  revealing a 
monoclonal pattern in peripheral blood leukocytes (1  1,  monocytes 
(2). granulocytes (3). and T lymphocytes (4). A polyclonal pattern 
is observed in skin fibroblasts (5). 
patient  1.  However, the inequality of  the two autoradio- 
graphic bands after Hpu 11 digestion indicates in all likeli- 
hood that the weaker 0.9 kb fragment stems from admixed 
polyclonal lymphocytes, thus masking a clonal monocyte cell 
population (Fig I A, lane 2). 
DISCUSSION 
Essential thrombocythemia is  the least common chronic 
myeloproliferative disorder,  with  an  annual  incidence of 
approximately  0.1  in  100,OOO.’”  To  our  knowledge,  the 
development of  ET in siblings has previously been reported 
only  once.”  Familial  occurrence,  however,  is  known  in 
polycythemia vera (PV), another mydoproliferative disorder 
closely linked to ET. In the large series of the Polycythemia 
Study Group, approximately 6% of  the patients had family 
members with  the  same  disease.”  The close relationship 
between ET and PV can be derived from the observation that 
a  proportion of  patients  with  ET convert  to  PV.’”  This 
clinical  course  is  also  noticed  in  patient  1;  her  clinical 
phenotype changed after 4 years of  follow-up from ET to PV. 
The molecular  basis,  however,  for  both  the transition  in 
clinical manifestation and the familial occurrence of  these 
diseases remains to be elucidated. 
The fact that up to  5% of  PV  and ET cases evolve into 
acute leukemia might indicate the premalignant  nature of 
these  disorder^.^^^.^^^^^  Along this line, clonal analysis based 
on X-chromosome inactivation studies convincingly estab- 
lished the clonal nature of  hematopoiesis in both patients and 
thus confirmed the clinical diagnosis of ET. We would like to 
emphasize that this type of investigation is applicable to 50% 
of female patients and may have potential as a diagnostic tool 
in the differential diagnosis between clonal myeloprolifera- 
tive disorders and reactive proces~es.’~.’~ 
Interestingly,  the t.ransformation event  in both  patients 
apparently occurred at  different stem cell levels. In patient 2, 
granulocytes, monocytes. and T lymphocytes were clonally 
related, while skin fibroblasts showed the expected polyclonal 
X-inactivation pattern. Therefore, in this patient, transforma- 
tion must have affected a very early hematopoietic progenitor 
cell. In patient  I, only the granulocyte fraction exhibited a 
clear-cut monoclonal pattern, while T lymphocytes were by 
definition of a polyclonal nature. The pattern of the monocyte 
fraction was also polyclonal. However, the latter finding most 
likely reflects the admixture of polyclonal lymphoid contami- 
nants to a monoclonal monocyte population. Although clonal 
myelopoiesis without involvement of  the monocyte lineage 
has previously been  reported  in a unique ET patient,’  our 
interpretation  is  in  keeping with  the  current  view  that  a 
disease that is multipotent for at least megakaryocytes, red 
blood cells, and granulocytes should also include monocytes 
as  part of the clone. In any case, the disease originated in this 
patient  from  a  more  committed  progenitor  cell  without 
capacity to differentiate into the lymphoid lineage. 
Heterogeneity  at the affected  stem  cell  level  has  been 
demonstrated in other hematopoietic disorders, such as  acute 
myeloid  leukemia  (AML),  Ph-positive  leukemia,  and 
lymph~ma.~’’~~  These biologic differences might bear clinical 
significance. A case  in point  is the recent  observation of 
Fialkow et al that in  AML patients after chemotherapy, 
cases originating  from a multipotent  stem cell  may evolve 
into a clonal remission, in contrast to leukemias derived from 
a granulocyte progenitor ceII.” 
Thus far, the meaning, if any, of differences at the stem 
cell  level  to the clinical evolution of  ET or other chronic 
myeloproliferative  disorders  remains  obscure.  This  issue 
merits further studies. 
NOTE ADDED  IN PROOF 
We  recently performed X-inactivation analyses in  24 hetmzy- 
gous  c-MPD  patients  (17  PV,  4  ET,  3 IMF).  All  but one case 
exhibited clonal hematopoiesis. Cell separation analysis in one ET 
and three PV  patients demonstrated in all four cases a monoclonal 
pattern of  the granulocyte fraction, while T lymphocytes of  these 
patients were of  nonclonal origin.” 
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